

Audits conducted pursuant to 2 U.S.C. 437g, § 438(b), and Title 26, U.S.C.

Matters concerning participation in civil actions or proceedings or arbitration.

Internal personnel rules and procedures or matters affecting a particular employee.

DATE & TIME: Thursday, July 18, 2002 at 10 a.m.

PLACE: 999 E Street, NW., Washington DC, (Ninth Floor).

STATUS: This Meeting Will be Open to the Public.

ITEMS TO BE DISCUSSED:

Correction and Approval of Minutes.
Draft Advisory Opinion 2002-07: Careau & Co. and Mohre Communications by Robert F. Carrot, President.

Administrative Matters.

PERSON TO CONTACT FOR INFORMATION:
Mr. Ron Harris, Press Officer,
Telephone: (202) 694-1220.

Mary W. Dove,

Secretary of the Commission.

[FR Doc. 02-17517 Filed 7-9-02; 11:37 am]

BILLING CODE 6715-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committee; Renewals

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the

renewal of certain FDA advisory committees by the Deputy Commissioner of Food and Drugs (the Deputy Commissioner). The Deputy Commissioner has determined that it is in the public interest to renew the charters of the committees listed in the following table for an additional 2 years beyond charter expiration date. The new charters will be in effect until the dates of expiration listed in the following table. This notice is issued under the Federal Advisory Committee Act of October 6, 1972 (Public Law 92-463 (5 U.S.C. app. 2)).

DATES: Authority for these committees will expire on the dates indicated in the following table unless the Deputy Commissioner formally determines that renewal is in the public interest.

Name of committee	Date of expiration
Medical Imaging Drugs Advisory Committee	February 28, 2004
Gastrointestinal Drugs Advisory Committee	March 3, 2004
Advisory Committee for Reproductive Health Drugs	March 23, 2004
Arthritis Advisory Committee	April 5, 2004
Veterinary Medicine Advisory Committee	April 24, 2004
Anesthetic and Life Support Drugs Advisory Committee	May 1, 2004
Blood Products Advisory Committee	May 13, 2004
Pulmonary-Allergy Drugs Advisory Committee	May 30, 2004
Drug Safety and Risk Management Advisory Committee (formerly Drug Abuse Advisory Committee)	May 31, 2004
Science Advisory Board/NCTR	June 2, 2004
Peripheral and Central Nervous System Drugs Advisory Committee	June 4, 2004
Psychopharmacologic Drugs Advisory Committee	June 4, 2004
Transmissible Spongiform Encephalopathies Advisory Committee	June 9, 2004

FOR FURTHER INFORMATION CONTACT:

Linda A. Sherman, Advisory Committee Oversight and Management Staff (HF-4), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1220.

Dated: July 5, 2002.

William K. Hubbard,

Senior Associate Commissioner for Policy, Planning, and Legislation.

[FR Doc. 02-17478 Filed 7-10-02; 8:45 am]

BILLING CODE 4160-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Request for Nominations for Members on Public Advisory Committees; Drug Safety and Risk Management Advisory Committee (Formerly Drug Abuse Advisory Committee)

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is requesting nominations for four members to serve on the Drug Safety and Risk Management Advisory Committee in the Center for Drug Evaluation and Research.

FDA has a special interest in ensuring that women, minority groups, and the physically challenged are adequately represented on advisory committees and, therefore, extends particular encouragement to nominations for appropriately qualified female, minority, or physically challenged candidates. Final selection from each vacancy will be determined by the expertise required to meet specific agency needs and in a manner to ensure appropriate balance on membership.

DATES: Nominations should be received before September 1, 2002.

ADDRESSES: All nominations for membership should be sent to Kimberly Topper, and all nominations for consumer-nominated members should be sent to Linda Sherman (see **FOR FURTHER INFORMATION CONTACT**).

FOR FURTHER INFORMATION CONTACT:

Kimberly Topper, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-7001, e-mail: topperk@cder.fda.gov; or

Linda Sherman, Advisory Committee Oversight and Management Staff (HF-4), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1220, e-mail: lsberman@oc.fda.gov.

SUPPLEMENTARY INFORMATION: On June 1, 2002, the Drug Safety and Risk Management Advisory Committee (formerly Drug Abuse Advisory Committee) was rechartered with 9 of the proposed 13 members. Accordingly, FDA is requesting nominations for members to serve on the Drug Safety and Risk Management Advisory Committee (formerly Drug Abuse Advisory Committee).

Function: The committee advises the Commissioner of Food and Drugs regarding the scientific and medical evaluation of all information gathered